BRIEF published on 08/08/2025 at 02:20, 7 months 15 days ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
PRESS RELEASE published on 08/08/2025 at 02:15, 7 months 15 days ago CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech CureVac resolves patent litigation with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines, receiving $790 million and non-exclusive license agreements BioNTech MRNA Technology CureVac Patent Litigation Pfizer
BRIEF published on 06/24/2025 at 22:14, 8 months 28 days ago CureVac publie les résultats de son assemblée générale annuelle CureVac Nominations Au Conseil D'administration Commissaires Aux Comptes Technologie De L'ARNm Assemblée Annuelle
BRIEF published on 06/24/2025 at 22:14, 8 months 28 days ago CureVac Reports Outcomes of Annual General Meeting MRNA Technology Annual Meeting Board Appointments Auditors CureVac
PRESS RELEASE published on 06/24/2025 at 22:09, 8 months 28 days ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of Annual General Meeting, including new Management Board and Supervisory Board appointments. KPMG reappointed as external auditors Annual General Meeting Appointments Voting Results KPMG CureVac
BRIEF published on 05/20/2025 at 13:05, 10 months 2 days ago CureVac Reports Q1 2025 Financials and Business Developments Financial Results Revenue Patents Oncology Pipeline R&D Developments
BRIEF published on 05/20/2025 at 13:05, 10 months 2 days ago CureVac publie ses résultats financiers et ses développements commerciaux pour le premier trimestre 2025 Résultats Financiers Brevets Revenu Pipeline En Oncologie Développements En R&D
PRESS RELEASE published on 05/20/2025 at 13:00, 10 months 2 days ago CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates CureVac announces financial results for Q1 2025 and updates on lung cancer and glioblastoma trials, urinary tract infection vaccine, and mRNA patents. Cash position strong at €438.3 million Financial Results Oncology Pipeline CureVac Q1 2025 MRNA Patents
BRIEF published on 05/15/2025 at 22:15, 10 months 7 days ago CureVac Gains Favorable Patent Decision Against BioNTech BioNTech MRNA Technology CureVac Patent Litigation European Patent Office
BRIEF published on 05/15/2025 at 22:15, 10 months 7 days ago CureVac obtient une décision favorable en matière de brevets contre BioNTech BioNTech CureVac Technologie De L'ARNm Office Européen Des Brevets Litiges En Matière De Brevets
Published on 03/23/2026 at 02:00, 2 hours 29 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/20/2026 at 13:30, 2 days 14 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/23/2026 at 03:35, 54 minutes ago Deye 2026 Frankfurt Distributor & Partner Summit Concludes Successfully
Published on 03/22/2026 at 12:23, 16 hours 6 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 2 days 5 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 2 days 7 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 19:00, 2 days 9 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 9 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 10 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 10 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
